What Did Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Take Home Last Year?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
Nancy Simonian has been the CEO of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) since 2012. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider the growth in the business. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to consider the appropriateness of CEO pay levels.
See our latest analysis for Syros Pharmaceuticals
How Does Nancy Simonian's Compensation Compare With Similar Sized Companies?
Our data indicates that Syros Pharmaceuticals, Inc. is worth US$306m, and total annual CEO compensation is US$3.0m. (This figure is for the year to December 2018). Notably, that's an increase of 36% over the year before. While we always look at total compensation first, we note that the salary component is less, at US$560k. We examined companies with market caps from US$200m to US$800m, and discovered that the median CEO total compensation of that group was US$1.7m.
As you can see, Nancy Simonian is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Syros Pharmaceuticals, Inc. is paying too much. A closer look at the performance of the underlying business will give us a better idea about whether the pay is particularly generous.
You can see a visual representation of the CEO compensation at Syros Pharmaceuticals, below.
Is Syros Pharmaceuticals, Inc. Growing?
On average over the last three years, Syros Pharmaceuticals, Inc. has grown earnings per share (EPS) by 92% each year (using a line of best fit). It achieved revenue growth of 477% over the last year.
This demonstrates that the company has been improving recently. A good result. It's great to see that revenue growth is strong, too. These metrics suggest the business is growing strongly. Shareholders might be interested in this free visualization of analyst forecasts.
Has Syros Pharmaceuticals, Inc. Been A Good Investment?
With a three year total loss of 60%, Syros Pharmaceuticals, Inc. would certainly have some dissatisfied shareholders. So shareholders would probably think the company shouldn't be too generous with CEO compensation.
In Summary...
We compared the total CEO remuneration paid by Syros Pharmaceuticals, Inc., and compared it to remuneration at a group of similar sized companies. As discussed above, we discovered that the company pays more than the median of that group.
Importantly, though, the company has impressed with its earnings per share growth, over three years. On the other hand returns to investors over the same period have probably disappointed many. This doesn't look great when you consider CEO remuneration is up on last year. Considering the per share profit growth, but keeping in mind the weak returns, we'd need more time to form a view on CEO compensation. Whatever your view on compensation, you might want to check if insiders are buying or selling Syros Pharmaceuticals shares (free trial).
If you want to buy a stock that is better than Syros Pharmaceuticals, this free list of high return, low debt companies is a great place to look.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.
